Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus

• Published in: Lupus Vol. 27; no. 13; pp. 2093 - 2100
• Main Authors: Miyawaki, Y, Sada, K, Asano, Y, Hayashi, K, Yamamura, Y, Hiramatsu, S, Ohashi, K, Morishita, M, Watanabe, H, Matsumoto, Y, Kawabata, T, Wada, J
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-11-2018; Sage Publications Ltd
• Subjects: Adult; Anti-DNA antibodies; Antibodies, Antinuclear - blood; Complement C3 - analysis; Complement C4 - analysis; Complement component C3; Complement component C4; Female; Humans; Hypocomplementemia; Lupus; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - immunology; Male; Middle Aged; Prednisolone; Recurrence; Remission; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Systemic lupus erythematosus; Young Adult; anti-dsDNA antibodies; Systemic lupus erythematosus; progressive reduction; relapse; hypocomplementemia
• ISSN: 0961-2033; 1477-0962
• DOI: 10.1177/0961203318804892

Objective
Serologically active clinically quiescent (SACQ)-SLE is a subtype of systemic lupus erythematosus (SLE); most SACQ-SLE patients relapse. Although complement and/or anti-dsDNA level fluctuations during SACQ status are reportedly not useful for predicting relapse, they might be useful in specific clinical settings. We aimed to assess the correlation between future relapse and progressive reductions in serum complement levels following remission in patients with hypocomplementemia.
Methods
We retrospectively reviewed patients aged ≥15 years who were treated with ≥20 mg/day of prednisolone for remission induction. After achieving remission, the patients treated with prednisolone tapered to ≤15 mg/day without relapse and followed by hypocomplementemia (first hypocomplementemia point) were analyzed. The primary outcome was the relapse during the first 24 months.
Results
Seventy-six patients were enrolled; 31 (40.8%) relapsed. A ≥10% reduction after the first hypocomplementemia point in serum C3, C4, and CH50 levels was found in 10, 21, and 16 patients, respectively. Hazard ratios (95% confidence intervals) for relapse were 2.32 (0.92–5.12) for serum C3 levels and 2.46 (1.18–5.01) for serum C4 levels. Progressive reductions in serum C3 and C4 levels had relatively high specificity (93.3% and 82.2%) but limited sensitivity (22.6% and 41.9%) for predicting relapse. However, simultaneous progressive reduction in C3 levels and increase in anti-dsDNA antibody levels had the highest specificity (97.8%), and simultaneous progressive reduction in C4 levels or increase in anti-dsDNA antibody levels had the highest sensitivity (71.0%).
Conclusion
Simultaneous progressive reductions in complement levels and increases in anti-dsDNA antibody levels may indicate future relapse SACQ-SLE patients.